Mycophenolate Mofetil Drug Asset Due Diligence Report 2026

This Mycophenolate Mofetil Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

1053

Registered trials

616

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Mycophenolate Mofetil can convert its Small molecule drug profile and IMPDH biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Mycophenolate Mofetil (query alias: mycophenolic acid)
Modality / target	Small molecule drug; IMPDH; IMPDH inhibitors
Highest global status	Approved
Originator	Syntex Pharmaceuticals Ltd.
Active developers	Fred Hutchinson Cancer Research Center, City of Hope National Medical Center, The Fox Chase Cancer Center

The MCP disease footprint includes Nephrotic Syndrome, Interstitial lung disease due to systemic disease, Hematopoietic stem cell transplantation. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT1051260099	Phase 2	募集中	38	1 year GVHD-free, relapse-free survival (GRFS)
NCT07663422	Phase 2	Not yet recruiting	31	Response rate of immunotherapy (IO)-related hepatitis to MMF and prednisone
ChiCTR2600127808	Phase 1	Completed	2	Graft and Recipient Survival Rates

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

MAY TRIPLE COMBINATION THERAPY STOP INTERSTITIAL LUNG DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS? EVIDENCE FROM REAL-LIFE DATA

Not Applicable; n=51; evaluation: Positive. Reported fields: AE = 22.0 % ; AE = 27.0 %

COMBINATION OF NINTEDANIB WITH DUAL IMMUNOSUPPRESSION IN SSC-ILD AND RA-ILD: A SYSTEMATIC REVIEW AND POOLED MULTICENTRE REAL-WORLD COHORT STUDY

Not Applicable; n=64; evaluation: Positive. Reported fields: -; DLCO(12-month) = -0.1 %

COMPLETE AND PARTIAL RENAL RESPONSE TO VOCLOSPORIN IN DIFFICULT-TO-TREAT PATIENTS WITH LUPUS NEPHRITIS: DATA FROM THE VORLISS (VOCLOSPORIN IN REAL LIFE SETTING STUDY)

Not Applicable; n=77; evaluation: Positive. Reported fields: CRR = 28.0 % ; -; CRR = 22.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Mycophenolate Mofetil addresses Nephrotic Syndrome, Interstitial lung disease due to systemic disease, Hematopoietic stem cell transplantation. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2003-07-01	Aspreva Pharmaceuticals sign An agreement with Roche	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO